Fundamental Data for CEPH

CEPHALON I(NSDQ:CEPH)

Cephalon is an international biopharmaceutical company focused on thediscovery, development and marketing of products to treat sleep disorders,neurological disorders, cancer and pain. In addition to an active research and development program, they market products in the United States and various countries in Europe.

# Employees: 2780

Address: 41 Moores Road,Frazer,PA,USA

Phone: 610 344-0200

Fax: 610 738-6590

Website: www.cephalon.com

Email: investorrelations@cephalon.com

Sector: Medical

Industry: MED-BIOMED/GENE

Executive Officers

Frank Baldino Jr. (Chmn.; C.E.O.)

Kevin J. Buchi (Exec. V.P.; C.F.O.)

William P. Egan (Dir.)

Martyn D. Greenacre (Dir.)

Vaughn M. Kailian (Dir.,)

Dividend

Ex-Dividend Date: N/A

Annual Dividend: N/A

Current Dividend Yield: N/A

Dividend Paid (3 months): N/A

Indicated Dividend: N/A

Earnings

Last Earnings Date: 9/30/2009

Next Earnings Date(Expected): 2/11/2010

Mean EPS (Next Qtr): $1.58

Mean EPS (Year): $5.94

Mean Estimate(Long Term): $13.09

P/E Ratio(Based on EPS estimate): 10.040

Number of Estimates: 25

Shares Performance

Period	CEPH	Compare to S&P
YTD	-22.63 %	-35.96 %
4 Weeks	10.55 %	9.36 %
12 Weeks	6.01 %	-0.06 %

Shares Information

Analyst Coverage: Y

Avg Volume: 2197462

Shares Outstanding: 74M

Market Cap: $4.45B

52 Week High: $80.26

52 Week Low: $53.26

P/E Ratio: 10.240

PEG Ratio: 0.770

Split: On 1/1/1990 CEPH split by factor of 0.080

Earnings Performance

EPS Growth in Last Quarter: 12.50 %

EPS Growth in Last Year: 37.29 %

Sales Growth in Last Quarter: 0.29 %

Sales Growth in Last Quarter: 10.22 %

Financials

Qtr Book Value: $1.83

Cash Flow/Share: $7.57

Change in Payout Ratio: 0.000

Price/Sales: 2.060